During this process, technology transfer offices at universities and research institutes are challenged with providing all of the documentation and information needed for potential licensees to evaluate a technology, without losing control of the underlying intellectual property or violating open records regulations. More and more technology transfer offices across the globe are finding that a secure virtual data room is the ideal platform for managing and protecting the technology transfer process.
Topics: Tech Transfer
A virtual data room is the ideal platform for the simple, secure and organized sharing of confidential documents with third parties during due diligence for M&A, partnering, fundraising, and asset sales. But not all data rooms are created equal.
When shopping for a virtual data room, look for one that provides the highest level of features and functionality, but also one that is intuitive to use and quick to deploy.
A good virtual data room should require very limited training and should be able to be populated with comprehensive due diligence materials in the matter of an hour or two, not days. When evaluating virtual data rooms for your application, look for the following characteristics and features:
- DOCUMENT CONTROL
At the heart of any modern virtual data room is the ability to secure and control sensitive documents while sharing them with third parties. A good virtual data room utilizes enterprise-grade security, even on computers and devices that are outside the control of a firm’s IT department. This security technology should be applied uniformly, regardless of whether documents are viewed on Windows, Macs, or iOS devices.
June 15th – 18th, 2015 | Philadelphia
The BIO International Convention is hosted by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
BIO performs many services for members, but none of them are more visible than the BIO International Convention, an event that helps BIO fulfill its mission to help grow the global biotech industry. Profits from the BIO International Convention are returned to the biotechnology industry by supporting BIO programs and initiatives. BIO also works throughout the year to create a policy environment that enables the industry to pursue its vision of bettering the world through biotechnology innovation.
Here at ShareVault we know that growing a life science company isn't easy. Sometimes it feels like a lonely battle when you’re trying to secure the goods and services your company needs to survive. Why go it alone? The Biotechnology Industry Organization (BIO) has created the industry’s largest cost-saving program: BIO Business Solutions®.
According to TechTarget, "Rogue IT" is the use of unsanctioned information technology resources within an organization. Is your company heading down the slippery slope of rogue IT? Are your employees downloading unauthorized apps on personal devices or using Dropbox, Google Docs, or other SaaS platforms that can lead to document leakages, lost business and financial penalties? When employees begin relying on their personal smartphones and cloud apps to get “anywhere, anytime” access to company systems and data, they no longer see the need for the IT middleman. It’s known as “Shadow IT” and it’s definitely a problem in today’s enterprise. Enterprise IT vendor harmon.ie recently ran a competition to highlight the problem. They asked participants to provide the best (or worst, depending on your perspective) example of rogue IT gone wrong. Here are the winners:
February 22 – 25, 2015—Hyatt Regency, New Orleans
Crawfish Étouffée anyone? One of the best reasons to visit New Orleans is that you get to try authentic food that you can’t find anywhere else in the country. But for us here at ShareVault, the New Orleans’ cuisine is just a bonus—our primary interest is attending the Association of University Technology Managers Annual Meeting and to introduce its members to ShareVault’s secure document sharing platform.
We’re excited to be attending this year’s BIO CEO & Investor Conference February 9-10 at the Waldorf Astoria in New York. We hope you’ll be there too and that we’ll have the opportunity to meet. If you haven’t yet registered, you can do so below. Don’t miss this important opportunity to connect with the great mix of investors attending the event.
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because BIO's mission is to support industry-wide success, this conference presents a broad and unbiased view of investment opportunities. And, qualified investors can attend for free!
After extremely weak performance in early 2014, the biotechnology industry understandably dropped off the radar of many investors. And, even though the industry has quietly been making a comeback, cautious investors are still concerned with the volatility in the market.
The fact is, despite the current climate of optimism, raising capital in the biotechnology industry has been especially challenging in the past five years, particularly for early-stage companies. Numerous factors, including a challenging FDA environment upon NDA submission, long timelines to approval and the high rate of drug failure, have contributed to a skeptical venture capitalist view of the sector’s prospects. As a result, emerging growth biotechnology companies are increasingly pursuing alternative financing vehicles, including equity crowdfunding, to advance their drug development programs.
This webinar, which takes place at 6:00 am Pacific Time on Thursday, January 29, will provide insight into unique methods employed when valuing products and companies in biotech. For example: How is a DCF model different for these high growth drug R&D companies? What are Real Options and when should they be used? If you have a background in finance, are new to the world of biotech valuation, or are new to the Real Options approach to valuation, then this webinar is for you.